ALERT: Rosen Law Firm Reminds Northwest Biotherapeutics, Inc. Investors of Important Class Action Deadline
September 10 2015 - 1:40PM
Business Wire
Rosen Law Firm, a global investor rights law firm, reminds
purchasers of Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)
securities from March 8, 2013 through August 20, 2015, all dates
inclusive (the “Class Period”) of the important October 26, 2015
lead plaintiff deadline. The lawsuit seeks to recover damages for
Northwest Biotherapeutics, Inc. investors under the federal
securities laws.
To join the Northwest Biotherapeutics, Inc. class action, go to
the firm’s website at http://www.rosenlegal.com/cases-299.html or
call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at
866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com
for information on the class action. The lawsuit is pending in U.S.
District Court for the District of Maryland.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A
CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU
RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO
NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants made false and/or
misleading statements and/or failed to disclose that: (1) Northwest
Biotherapeutics’ claims concerning positive results from its
DCVax-Direct Trial were based on preliminary and unverified trial
results; (2) the DCVax-Direct Trial results on which Northwest
Biotherapeutics reported had not been assessed or examined by the
hospitals conducting the trials; (3) Northwest Biotherapeutics’
statements about DCVax-Direct were derived from patient case report
forms that the hospitals were obliged to send to Northwest
Biotherapeutics only because it sponsored the study; (4) Northwest
Biotherapeutics was the subject of an aggressive stock promotion
campaign which included promoters using fictitious identities and
false credentials; (5) German regulators required additional
information from Northwest Biotherapeutics so that the DCVax-L
Trial could continue uninterrupted; and (6) consequently, Northwest
Biotherapeutics’ financial statements were materially false and
misleading at all relevant times. When the true details entered the
market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to
serve as lead plaintiff, you must move the Court no later than
October 26, 2015. A lead plaintiff is a representative party acting
on behalf of other class members in directing the litigation. If
you wish to join the litigation, go to the firm’s website at
http://www.rosenlegal.com/cases-299.html or to discuss your rights
or interests regarding this class action, please contact Phillip
Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
kchan@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150910006498/en/
The Rosen Law Firm, P.A.Laurence Rosen, Esq.Phillip Kim,
Esq.Kevin Chan, Esq.275 Madison Avenue, 34th FloorNew York, NY
10016Tel: 212-686-1060Toll Free: 866-767-3653Fax:
212-202-3827lrosen@rosenlegal.compkim@rosenlegal.comkchan@rosenlegal.comwww.rosenlegal.com
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2023 to Apr 2024